The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection

SIMPLE SUMMARY: Circulating tumour DNA (ctDNA) has been shown to be an informative biomarker in melanoma. Here we analysed plasma ctDNA in a real-world metastatic melanoma cohort. We found the kinetics of ctDNA decline are delayed in patients treated with immunotherapy compared to those receiving MA...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Marsavela, Gabriela, Johansson, Peter A., Pereira, Michelle R., McEvoy, Ashleigh C., Reid, Anna L., Robinson, Cleo, Warburton, Lydia, Khattak, Muhammad A., Meniawy, Tarek M., Amanuel, Benhur, Millward, Michael, Hayward, Nicholas K., Ziman, Melanie R., Gray, Elin S., Calapre, Leslie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7765660/
https://ncbi.nlm.nih.gov/pubmed/33339135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123793
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller